Exportin 1 inhibition prevents neuroendocrine transformation through SOX2 down-regulation in lung and prostate cancers Journal Article
| Authors: | Quintanal-Villalonga, A.; Durani, V.; Sabet, A.; Redin, E.; Kawasaki, K.; Shafer, M.; Karthaus, W. R.; Zaidi, S.; Zhan, Y. A.; Manoj, P.; Sridhar, H.; Shah, N. S.; Chow, A.; Bhanot, U. K.; Linkov, I.; Asher, M.; Yu, H. A.; Qiu, J.; de Stanchina, E.; Patel, R. A.; Morrissey, C.; Haffner, M. C.; Koche, R. P.; Sawyers, C. L.; Rudin, C. M. |
| Article Title: | Exportin 1 inhibition prevents neuroendocrine transformation through SOX2 down-regulation in lung and prostate cancers |
| Abstract: | In lung and prostate adenocarcinomas, neuroendocrine (NE) transformation to an aggressive derivative resembling small cell lung cancer (SCLC) is associated with poor prognosis. We previously described dependency of SCLC on the nuclear transporter exportin 1. Here, we explored the role of exportin 1 in NE transformation. We observed up-regulated exportin 1 in lung and prostate pretransformation adenocarcinomas. Exportin 1 was up-regulated after genetic inactivation of TP53 and RB1 in lung and prostate adenocarcinoma cell lines, accompanied by increased sensitivity to the exportin 1 inhibitor selinexor in vitro. Exportin 1 inhibition prevented NE transformation in different TP53/RB1-inactivated prostate adenocarcinoma xenograft models that acquire NE features upon treatment with the aromatase inhibitor enzalutamide and extended response to the EGFR inhibitor osimertinib in a lung cancer transformation patient-derived xenograft (PDX) model exhibiting combined adenocarcinoma/SCLC histology. Ectopic SOX2 expression restored the enzalutamide-promoted NE phenotype on adenocarcinoma-to-NE transformation xenograft models despite selinexor treatment. Selinexor sensitized NE-transformed lung and prostate small cell carcinoma PDXs to standard cytotoxics. Together, these data nominate exportin 1 inhibition as a potential therapeutic target to constrain lineage plasticity and prevent or treat NE transformation in lung and prostate adenocarcinoma. |
| Keywords: | genetics; adenocarcinoma; metabolism; lung neoplasms; down-regulation; pathology; prostatic neoplasms; lung tumor; prostate tumor; lung; down regulation; soxb1 transcription factors; sox2 protein, human; transcription factor sox; small cell lung cancer; small cell lung carcinoma; enzalutamide; humans; human; male; selinexor; exportin 1 protein |
| Journal Title: | Science Translational Medicine |
| Volume: | 15 |
| Issue: | 707 |
| ISSN: | 1946-6234 |
| Publisher: | American Association for the Advancement of Science |
| Date Published: | 2023-08-02 |
| Start Page: | eadf7006 |
| Language: | English |
| DOI: | 10.1126/scitranslmed.adf7006 |
| PUBMED: | 37531417 |
| PROVIDER: | scopus |
| PMCID: | PMC10777207 |
| DOI/URL: | |
| Notes: | The MSK Cancer Center Support Grant (P30 CA008748) is acknowledged in the PubMed record and PDF. Corresponding MSK author are Alvaro Quintanal-Villalonga and Charles M. Rudin -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
Related MSK Work